An Early Phase 1 interventional study of Large liquid meal, spinal catheter and venous line in Obesity and Diabetes Mellitus, Type 2, sponsored by Mikkel Bring Christensen. Completed at 1 site in Denmark. Open to male participants aged 50 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Mikkel Bring Christensen · Early Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 351 studies in Obesity with a site in Denmark — 58 open to participants now, 85 under way, 23 of them phase 3. Obesity · Denmark.
Among the 351 studies in Obesity with a site in Denmark, this one is the 208th largest by enrollment of the 283 interventional ones that give a count, is one of 18 that started in 2023, is one of 14 in phase 1, and was the 272nd registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →58 of the 351 studies in Obesity with a site in Denmark are open now. Recruiting first, the newest first:
University Hospital, Gentofte, Copenhagen · Sites in Denmark
Ages 20–40 · Men only · Healthy volunteers
University of Copenhagen · Sites in Denmark
Ages 18–75 · Healthy volunteers
Signe Torekov · Sites in Denmark
Ages 5+ · Healthy volunteers
AstraZeneca · Sites in Denmark, United States, Argentina and 8 more countries
Ages 18+
Novo Nordisk A/S · Sites in Denmark, United States, Belgium and 7 more countries
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 50 Years to 70 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
351 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 26 · Phase 3 42 · Phase 4 18
First in 1983; this study’s year is marked. 18 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 72 across the 283 interventional studies, 93 across the 68 observational. Of the 233 that completed or were terminated, 14 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
65 of 351 have an industry lead sponsor. The 10 most frequent:
Mikkel Bring Christensen is the lead sponsor of 2 studies on the registry; none are open to participants now.
Mikkel Bring Christensen has 1 study filed under Obesity — fewer than ten, so there is no comparison to draw.
14 of the studies in Obesity with a site in Denmark that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06833749KeyBioscience AGEfficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis | 2026-11 |
| NCT07463495University of AarhusThe Metabolic Effects of Oral Tributyrin Administration | 2026-12 |
| NCT06624462Bjorn H. EbdrupEffectiveness of a Pragmatic, Metabolic Care Clinic for Patients With Severe Mental Illness - The Meta Care Clinic | 2026-12 |
Add all 14 to your calendar (.ics) → With an account.
Among the 351 studies in Obesity with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Overweight and obesity are rising in prevalence and becoming a growing threat to public health. Obesity is associated with an increased all-cause mortality, impaired quality of life, and numerous of disorders. Therapeutic strategies against obesity - which include an abundance of dietary and physical training programmes and pharmaceutical drugs to increase energy expenditure or limit appetite or gastro-intestinal fat absorption - have shown limited success on long term weight loss. Thus, overweight and associated conditions is becoming the new normal and there is a need for better understanding gut-to-brain signalling, hormonal and metabolic disturbances in overweight individuals.
The purpose of this health science research project is to describe the coinciding plasma and cerebrospinal fluid (CSF) profiles of selected biomarkers after co-ingestion of a meal and model pharmaceuticals in patients with overweight and/or type 2 diabetes compared to healthy control individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Large liquid meal, spinal catheter and venous line
Large liquid meal (e.g. Nutricia® Energy 500 ml (750 kcal) admixed paracetamol 1000 mg (for estimation of gastric emptying) and Caffeine (to prevent postspinal headache). Spinal catheter for 4 hours, with samples taken at one hour interval. 2 venous lines, one for saline and one for venous sampling every half hour
Appetite regulating hormones measured by specific immunoassays
Time frame: After 1 hour
Appetite regulating hormones measured by specific immunoassays
Time frame: After 2 hour
Appetite regulating hormones measured by specific immunoassays
Time frame: After 3 hours
Appetite regulating hormones measured by specific immunoassays
Time frame: After 4 hours
Metabolomics measured in blood and cerebrospinalfluid using mass spectrometry
Time frame: After 1 hour
Metabolomics measured in blood and cerebrospinalfluid using mass spectrometry
Time frame: After 2 hours
Metabolomics measured in blood and cerebrospinalfluid using mass spectrometry
Time frame: After 3 hours
Metabolomics measured in blood and cerebrospinalfluid using mass spectrometry
Time frame: After 4 hours
Proteomics measured in blood and cerebrospinalfluid using mass spectrometry
Time frame: After 1 hour
Proteomics measured in blood and cerebrospinalfluid using mass spectrometry
Time frame: After 2 hours
Proteomics measured in blood and cerebrospinalfluid using mass spectrometry
Time frame: After 3 hours
Proteomics measured in blood and cerebrospinalfluid using mass spectrometry
Time frame: After 4 hours
Peptidomics measured in blood and cerebrospinalfluid using mass spectrometry
Time frame: After 1 hour
Peptidomics measured in blood and cerebrospinalfluid using mass spectrometry
Time frame: After 2 hour
Peptidomics measured in blood and cerebrospinalfluid using mass spectrometry
Time frame: After 3 hours
Peptidomics measured in blood and cerebrospinalfluid using mass spectrometry
Time frame: After 4 hours
Paracetamol concentrations measured in blood and cerebrospinalfluid
Time frame: After 1 hour
Paracetamol concentrations measured in blood and cerebrospinalfluid
Time frame: After 2 hours
Paracetamol concentrations measured in blood and cerebrospinalfluid
Time frame: After 3 hours
Paracetamol concentrations measured in blood and cerebrospinalfluid
Time frame: After 4 hours
Caffeine concentrations measured in blood and cerebrospinalfluid
Time frame: After 1 hour
Caffeine concentrations measured in blood and cerebrospinalfluid
Time frame: After 2 hours
Caffeine concentrations measured in blood and cerebrospinalfluid
Time frame: After 3 hours
Caffeine concentrations measured in blood and cerebrospinalfluid
Time frame: After 4 hours
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2023 to primary completion in Aug 2024, 10 months.
Of 105 non-industry phase 1 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 57. This study's 10 months is below that.
Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Oct 2024 → Aug 2024 and completion Oct 2024 → Aug 2024.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mikkel Bring Christensen